Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-24-100712
Filing Date
2024-09-17
Accepted
2024-09-17 17:08:15
Documents
14

Document Format Files

Seq Description Document Type Size
1 424B5 tm2423681-5_424b5.htm 424B5 690298
2 EX-FILING FEES tm2423681d5_ex-fillingfees.htm   iXBRL EX-FILING FEES 41582
3 GRAPHIC lg_novartis-4c.jpg GRAPHIC 26070
  Complete submission text file 0001104659-24-100712.txt   939294

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2423681d5_ex-fillingfees_htm.xml XML 14446
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Filer) CIK: 0001114448 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-282133 | Film No.: 241305257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 608 FIFTH AVENUE NEW YORK NY 10020
Business Address 608 FIFTH AVENUE NEW YORK NY 10020 (212)307 1122
Novartis Capital CORP (Filer) CIK: 0001443411 (see all company filings)

EIN.: 263086456 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-282133-01 | Film No.: 241305258
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)